VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM – a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM.
Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolutionize the global anti-aging skincare market.
The announcement follows the recent decision to trademark GlycoProteMim. The extraordinary results from the active ingredient’s clinical trials prompted the company’s strategic decision to establish Sirona Laboratories, which will redefine its trajectory in the skincare industry.
“We’ve opted for a course of action that – is primed to transform, not just Sirona Biochem’s prospects, but that of the entire anti-aging market. We’re not just interested in GlycoProteMim’s value today; we want to build its legacy and set a global precedent. This isn’t just about proving its efficacy; it’s about setting a new benchmark for anti-aging skin treatments,” Verrico said.
Sirona Biochem is inviting major industry players to take notice, to partner, and to believe in a future where GlycoProteMim is the go-to ingredient for skin anti-aging. As part of the strategic leap into the aesthetic marketplace, Sirona Biochem plans to position itself for maximum growth and market expansion.
Christopher Hopton CPA, Chief Financial Officer of Sirona Biochem, commented on the launch, stating that the strategic decision aligns with the company’s commitment to shareholder value, innovation, and market leadership.
“By establishing Sirona Laboratories, we are not only maximizing the commercial potential of GlycoProteMim but also ensuring sustained growth and value creation for our shareholders,” Hopton added.
Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer at Sirona Biochem, expressed excitement about the scientific possibilities. “The company’s clinically proven science, combined with the unmet commercial opportunity, positions Sirona Laboratories at the forefront of skincare innovation. We are eager to leverage our expertise and take GlycoProteMim to new heights, while also setting a new benchmark for anti-aging treatments,” she said.
To support this ambitious initiative, the company said that it has already identified a team of seasoned industry experts who will play a crucial role in steering Sirona Laboratories toward success.
The company is actively engaging with private equity funds and collaborating with industry experts to develop Sirona Laboratories product line and commercial strategy. The company intends to finance the bulk of this project through private financial partnerships, while leveraging its parent company’s intellectual property.
Sirona Biochem aims to propel the subsidiary, which will be based in Europe, and its active ingredient into a new era of global recognition. The company is inviting the entire skin industry and stakeholders to stay tuned for further updates on the advancements and achievements of Sirona Laboratories. Stay updated by visiting their website at www.sirona-laboratories.com
About Sirona Biochem:
Sirona Biochem is a leading biotech company with a proprietary formulation platform technology. Specializing in cosmetic ingredients and drug discovery, Sirona Biochem has developed a process to stabilize carbohydrate molecules, improving efficacy and safety for different applications.
Sirona’s compounds are licensed to leading cosmetics and pharma companies worldwide, in return for licensing fees, milestone payments, and ongoing royalty payments. Sirona’s R&D unit laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Email: [email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based on current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information unless explicitly stated otherwise. Actual results, performance, or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Bay Street News
